Literature DB >> 20480545

Raloxifene and/or estradiol decrease anxiety-like and depressive-like behavior, whereas only estradiol increases carcinogen-induced tumorigenesis and uterine proliferation among ovariectomized rats.

Alicia A Walf1, Cheryl Anne Frye.   

Abstract

Controversy surrounds the efficacy and safety of 17beta-estradiol (E2)-mimetic therapies to women for treatment of menopausal symptoms. An important question is the nature of the trophic actions of E2-mimetics in the brain for behavioral processes versus in the periphery for beneficial effects related to osteoporosis, or unwanted proliferative effects in the reproductive tissues, such as mammary glands and uterus. Of recent interest are the effects of selective estrogen receptor modulators, which can have tissue specific actions, for these processes. In the present study, the effects were determined of E2 alone, or co-administered with a selective estrogen receptor modulator, raloxifene, for anxiety-like, depression-like, and trophic peripheral effects in ovariectomized rats that were exposed to a chemical carcinogen (7,12-dimethylbenz(a)anthracene), or not. Once per week, rats were administered vehicle, E2 (0.09 mg/kg) and/or raloxifene (1 mg/kg) subcutaneously 44-48 h before testing in a positive control, E2-dependent behavior (lordosis), depression (forced swim test), and anxiety (elevated plus maze) behavioral assays. In addition to behavioral endpoints, incidence and number of tumors, and tumor, pituitary gland, and uterine weight 14 weeks after carcinogen-exposure, and weekly hormone treatments, were analyzed. Rats administered 7,12-dimethylbenz(a)anthracene had an increased number and size of tumors, compared with vehicle treatment. E2 + raloxifene increased the number of tumors. Administration of E2 or E2 +raloxifene, but not raloxifene alone, increased pituitary and uterine weight, compared with vehicle administration. E2 or E2 + raloxifene, but not raloxifene alone, also increased the incidence of lordosis and reduced the depression-like behavior in the forced swim test (i.e. decreased time spent immobile) compared with vehicle administration. However, administration of E2 or raloxifene reduced anxiety behavior in the elevated plus maze (i.e. increased time spent on the open arms of the maze), compared with vehicle treatment. Together these data show that E2 and/or raloxifene can have some effects to alter the behavior of ovariectomized rodents, depending upon the task. As well, E2, with or without raloxifene, can also have clear trophic actions in peripheral tissues, such as carcinogen-induced tumors, uterus, and pituitary glands.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20480545      PMCID: PMC2885355          DOI: 10.1097/fbp.0b013e32833a5cb0

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  58 in total

1.  Hormonal environment in the induction of breast cancer in castrated rats using dimethylbenzanthracene: influence of the presence or absence of ovarian activity and of treatment with estradiol, tibolone, and raloxifene.

Authors:  Justo Callejo; Antonio Cano; Marilyn Medina; Miquel Villaronga; Eduardo Gonzalez-Bosquet; Joan Sabria; Jose-Maria Lailla
Journal:  Menopause       Date:  2005-09-01       Impact factor: 2.953

2.  Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats.

Authors:  H H Berendsen; A H Weekers; H J Kloosterboer
Journal:  Eur J Pharmacol       Date:  2001-05-04       Impact factor: 4.432

3.  Mood effect of raloxifene in postmenopausal women.

Authors:  Natalia B Jarkova; Ferenc Martenyi; Daiva Masanauskaite; Erin L Walls; Vera P Smetnik; Imre Pavo
Journal:  Maturitas       Date:  2002-05-20       Impact factor: 4.342

4.  Sex hormone-induced mammary carcinogenesis in female Noble rats: detection of differentially expressed genes.

Authors:  G Leung; S W Tsao; Y C Wong
Journal:  Breast Cancer Res Treat       Date:  2003-01       Impact factor: 4.872

5.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

Review 6.  Estrogen agonists/antagonists in combination with estrogen for prevention and treatment of menopause-associated signs and symptoms.

Authors:  Dale W Stovall; JoAnn V Pinkerton
Journal:  Womens Health (Lond)       Date:  2008-05

Review 7.  Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.

Authors:  Heidi D Nelson; Rongwei Fu; Jessica C Griffin; Peggy Nygren; M E Beth Smith; Linda Humphrey
Journal:  Ann Intern Med       Date:  2009-11-17       Impact factor: 25.391

Review 8.  Recent advances in selective estrogen receptor modulators for breast cancer.

Authors:  Tianlin Wang; Qidong You; Frank Shu-Gui Huang; Hua Xiang
Journal:  Mini Rev Med Chem       Date:  2009-09       Impact factor: 3.862

9.  Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer's disease.

Authors:  Kathleen O'Neill; Shuhua Chen; Roberta Diaz Brinton
Journal:  Exp Neurol       Date:  2004-01       Impact factor: 5.330

10.  Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus.

Authors:  Denis Stygar; Natalia Muravitskaya; Britt Eriksson; Håkan Eriksson; Lena Sahlin
Journal:  Reprod Biol Endocrinol       Date:  2003-05-07       Impact factor: 5.211

View more
  13 in total

Review 1.  Pre-treatment effects of peripheral tumors on brain and behavior: neuroinflammatory mechanisms in humans and rodents.

Authors:  Andrew Schrepf; Susan K Lutgendorf; Leah M Pyter
Journal:  Brain Behav Immun       Date:  2015-05-06       Impact factor: 7.217

2.  Conjugated equine estrogen, with medroxyprogesterone acetate, enhances formation of 5alpha-reduced progestogens and reduces anxiety-like behavior of middle-aged rats.

Authors:  Cheryl A Frye; Alicia A Walf; Jason J Paris
Journal:  Behav Pharmacol       Date:  2010-09       Impact factor: 2.293

3.  Progesterone increased β-endorphin innervation of the locus coeruleus, but ovarian steroids had no effect on noradrenergic neurodegeneration.

Authors:  Fernanda B Lima; Cristiane M Leite; Cynthia L Bethea; Janete A Anselmo-Franci
Journal:  Brain Res       Date:  2017-03-08       Impact factor: 3.252

4.  Anti-anxiety, cognitive, and steroid biosynthetic effects of an isoflavone-based dietary supplement are gonad and sex-dependent in rats.

Authors:  Jonathan Friedman; Cheryl Frye
Journal:  Brain Res       Date:  2010-12-15       Impact factor: 3.252

Review 5.  Neuroimmunology of the female brain across the lifespan: Plasticity to psychopathology.

Authors:  R M Barrientos; P J Brunton; K M Lenz; L Pyter; S J Spencer
Journal:  Brain Behav Immun       Date:  2019-03-11       Impact factor: 7.217

6.  Activation of amygdalar metabotropic glutamate receptors modulates anxiety, and risk assessment behaviors in ovariectomized estradiol-treated female rats.

Authors:  María De Jesús-Burgos; Vanessa Torres-Llenza; Nivia L Pérez-Acevedo
Journal:  Pharmacol Biochem Behav       Date:  2012-01-24       Impact factor: 3.533

7.  The short-term effects of estradiol, raloxifene, and a phytoestrogen in women with perimenopausal depression.

Authors:  Peter J Schmidt; Shau-Ming Wei; Pedro E Martinez; Rivka R Ben Dor; Gioia M Guerrieri; Paula P Palladino; Veronica L Harsh; Howard J Li; Paul Wakim; Lynnette K Nieman; David R Rubinow
Journal:  Menopause       Date:  2021-01-15       Impact factor: 3.310

8.  The Phytoestrogen Genistein Produces Similar Effects as 17β-Estradiol on Anxiety-Like Behavior in Rats at 12 Weeks after Ovariectomy.

Authors:  Juan Francisco Rodríguez-Landa; Jonathan Cueto-Escobedo; Abraham Puga-Olguín; Eduardo Rivadeneyra-Domínguez; Blandina Bernal-Morales; Emma Virginia Herrera-Huerta; Andrea Santos-Torres
Journal:  Biomed Res Int       Date:  2017-10-31       Impact factor: 3.411

9.  Novel oestrogen receptor β-selective ligand reduces obesity and depressive-like behaviour in ovariectomized mice.

Authors:  Daimei Sasayama; Nobuhiro Sugiyama; Shigeru Yonekubo; Akiko Pawlak; Hiroyasu Murasawa; Mie Nakamura; Morimichi Hayashi; Takashi Ogawa; Makoto Moro; Shinsuke Washizuka; Naoji Amano; Kazuhiro Hongo; Hideki Ohnota
Journal:  Sci Rep       Date:  2017-07-05       Impact factor: 4.379

10.  Republished study: long-term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize.

Authors:  Gilles-Eric Séralini; Emilie Clair; Robin Mesnage; Steeve Gress; Nicolas Defarge; Manuela Malatesta; Didier Hennequin; Joël Spiroux de Vendômois
Journal:  Environ Sci Eur       Date:  2014-06-24       Impact factor: 5.893

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.